The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty

Cardiology Journal

Volumn 20, Issue 6, 2013, Pages 577-582

  Szadkowska, Iwona ^a   Wlazeł, Rafał Nikodem ^a   Migała, Marta ^a   Szadkowski, Krzysztof ^a   Zielińska, Marzenna ^a   Paradowski, Marek ^a   Pawlicki, Lucjan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Biomarkers; Galectin 3; Heart failure; Myocardial infarction; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIURETIC AGENT; GALECTIN 3;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DIURETICS; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84890354566     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0157     Document Type: Article

References (20)

1. Yang RY, Rabinovich GA, Liu FT. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med, 2008; 13: e17-e39.
2. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004; 110: 3121-3128.
3. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expressionand secretion links macrophages to the promotion of renal fibrosis. Am J Pathol, 2008; 172: 288-298.
4. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA, 2006; 103: 5060-5065.
5. McMurray JJV, Adamopoulos S, Anke SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J, 2012; 33: 1787-1847.
6. Jaarsma T, van der Wal MHL, Lesman-Leegte I et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med, 2008; 168: 316-324.
7. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and longterm mortality in patients with acutely decompensated heart failure. Eur J Heart Fail, 2010; 12: 826-832.
8. Felker GM, Fiuzat M, Shaw LK et al. Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION Study. Circ Heart Fail, 2012; 5: 72-78.
9. Lok DJA, van der Meer P, Pieta W et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol, 2010; 99: 323-328.
10. Lopez-Andres N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail, 2012: 14: 74-81.
11. Gullestad L, Ueland T, Kjekshus J et al.; on behalf of the CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J, 2012; 33: 2290-2296.
12. de Boer RA, Lok DJA, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med, 2011; 43: 60-68.
13. Steg G, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012; 33: 2569-2619.
14. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 2999-3054.
15. Thygesen K, Alpert JS, Jaffe AS et al. The Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction: third universal definition of myocardial infarction. Eur Heart J, 2012; 33: 2551-2567.
16. Grandin EW, Jarolim P, Murphy SA et al. TIMI Study Group. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem, 2012; 58: 267-273.
17. Falcone C, Lucibello S, Mazzucchelli I et al. Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol, 2011; 24: 905-913.
18. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail, 2013 Jan 4 [Epub ahead of print].
19. de Boer RA, van Veldhuisen DJ, Gansevoort RT et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med, 2012; 272: 55-64.
20. Swartz MF, Fink GW, Sarwar MF et al. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol, 2012; 60: 1799-1806.